La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sinopharm Tech Holdings Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Sinopharm Tech Holdings.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Hospitality crescita degli utili	28.7%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Feb 02

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 29

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

Nov 24

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Sinopharm Tech Holdings non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SEHK:8156 - Stime future degli analisti e dati finanziari passati (HKD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	47	-29	-1	-1	N/A
9/30/2023	41	-17	N/A	N/A	N/A
6/30/2023	43	-11	5	5	N/A
3/31/2023	23	-55	N/A	N/A	N/A
12/31/2022	44	-59	7	7	N/A
9/30/2022	45	-74	N/A	N/A	N/A
6/30/2022	41	-88	-37	-37	N/A
3/31/2022	48	-98	N/A	N/A	N/A
12/31/2021	34	-106	-45	-40	N/A
9/30/2021	33	-111	N/A	N/A	N/A
6/30/2021	78	-106	-16	-6	N/A
3/31/2021	136	-160	N/A	N/A	N/A
12/31/2020	134	-158	0	27	N/A
9/30/2020	161	-162	N/A	N/A	N/A
6/30/2020	166	-161	1	24	N/A
3/31/2020	120	-49	N/A	N/A	N/A
12/31/2019	119	-45	-32	-31	N/A
9/30/2019	89	-38	N/A	N/A	N/A
6/30/2019	44	-47	-34	-34	N/A
3/31/2019	28	-42	N/A	N/A	N/A
12/31/2018	25	-49	-23	-23	N/A
9/30/2018	24	-58	N/A	N/A	N/A
6/30/2018	25	-61	-31	-30	N/A
3/31/2018	22	-156	N/A	N/A	N/A
12/31/2017	24	-164	-59	-55	N/A
9/30/2017	25	-172	N/A	N/A	N/A
6/30/2017	26	-175	N/A	-59	N/A
3/31/2017	32	-223	N/A	N/A	N/A
12/31/2016	29	-222	N/A	-52	N/A
9/30/2016	26	-218	N/A	N/A	N/A
6/30/2016	35	-207	N/A	-39	N/A
3/31/2016	27	-63	N/A	N/A	N/A
12/31/2015	78	-22	N/A	-34	N/A
9/30/2015	121	8	N/A	N/A	N/A
6/30/2015	124	19	N/A	-13	N/A
3/31/2015	135	37	N/A	N/A	N/A
12/31/2014	131	36	N/A	8	N/A
9/30/2014	103	25	N/A	N/A	N/A
6/30/2014	96	15	N/A	0	N/A
3/31/2014	90	-11	N/A	N/A	N/A
12/31/2013	52	-20	N/A	-10	N/A
9/30/2013	42	-36	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 8156 è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 8156 cresceranno più velocemente del mercato Hong Kong

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 8156 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di 8156 cresceranno più rapidamente del mercato Hong Kong.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di 8156 cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 8156 è previsto essere elevato tra 3 anni

Sinopharm Tech Holdings Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023

Sinopharm Tech Holdings Provides Earnings Guidance for the Six Months Ended December 31, 2022

Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022

Recent updates

Second quarter 2024 earnings released: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)

Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023

First quarter 2024 earnings released: HK$0.013 loss per share (vs HK$0.024 profit in 1Q 2023)

Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023

Full year 2023 earnings released: HK$0.001 loss per share (vs HK$0.49 loss in FY 2022)

Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023

Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023

Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination Committee

New major risk - Share price stability

Third quarter 2023 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 3Q 2022)

Sinopharm Tech Holdings Limited Announces the Resignation of LAM Kit Sun as Independent Non-Executive Director, Member of the Audit Committee and the Remuneration Committee and the Chairperson and Member of the Nomination Committee

Second quarter 2023 earnings released: EPS: HK$0.002 (vs HK$0.001 loss in 2Q 2022)

Sinopharm Tech Holdings Provides Earnings Guidance for the Six Months Ended December 31, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: EPS: HK$0.001 (vs HK$0.002 loss in 1Q 2022)

Less than half of directors are independent

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 16, 2022

Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022

Sinopharm Tech Holdings Limited to Report Q1, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: HK$0.02 loss per share (vs HK$0.025 loss in FY 2021)

Sinopharm Tech Holdings Limited to Report Fiscal Year 2022 Results on Sep 30, 2022

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited Announces Management Changes

Chan Ting Resigns as CEO of Sinopharm Tech Holdings Limited

Third quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.004 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

First quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.001 loss in 1Q 2021)

Full year 2021 earnings released: HK$0.025 loss per share (vs HK$0.039 loss in FY 2020)

Insider recently bought HK$15m worth of stock

Co-Founder & Non-Executive Director Tung Mei Chan has left the company

Third quarter 2021 earnings released: HK$0.004 loss per share (vs HK$0.004 loss in 3Q 2020)

Sinopharm Tech Holdings Limited (SEHK:8156) entered into a sale and purchase agreement to acquire 25% stake in Shenzhen Ficus Technology Holdings Ltd. from Sharp Associates Limited for HKD 200 million.

New 90-day high: HK$0.29

Second quarter 2021 earnings released: HK$0.002 loss per share (vs HK$0.003 loss in 2Q 2020)

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Sinopharm Tech Holdings Limited to Report First Half, 2021 Results on Feb 10, 2021

Sinopharm Tech Holdings Limited Announces Board Changes

New 90-day high: HK$0.22

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: HK$0.20

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

First quarter 2021 earnings released: HK$0.001 loss per share

Sinopharm Tech Holdings Limited to Report Q1, 2021 Results on Nov 12, 2020

Full year earnings released - HK$0.039 loss per share

Sinopharm Tech Holdings Limited(SEHK:8156) dropped from S&P Global BMI Index

Sinopharm Tech Holdings Limited to Report Fiscal Year 2020 Results on Sep 29, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita